Table 1 Baseline characteristics of the 100 study participants
|  | All patients (n = 100) | ICM (n = 39) | NICM (n = 44) | Dual pathology (n = 17) | P-value |
|---|---|---|---|---|---|
Median age (years) | 69 (59–73) | 69 (54–84) | 69 (50–88) | 69 (57–81) | 0.984 |
Gender | 77% M, 33% F | 77% M, 33% F | 70% M, 30% F | 94% M, 6% F | Â |
SBP (mmHg) | 134.7 ± 23.7 | 135.9 ± 24.4 | 132.0 ± 19.8 | 134.5 ± 30.7 | 0.715 |
DBP (mmHg) | 79.9 ± 14.8 | 79.7 ± 13.2 | 80.3 ± 14.5 | 77.6 ± 20.2 | 0.824 |
Pulse rate (beats/min) | 72.3 ± 14.1 | 69.9 ± 12.4 | 75.1 ± 16.3 | 71.9 ± 11.4 | 0.263 |
ACEI (%) | 73 | 72 | 71 | 83 | 0.68 |
ARB (%) | 13 | 19 | 9 | 8 | 0.426 |
Beta blocker (%) | 82 | 84 | 76 | 92 | 0.419 |
Loop diuretic (%) | 51 | 50 | 53 | 50 | 0.967 |
Thiazide diuretic (%) | 1 | 0 | 3 | 0 | 0.519 |
Aldosterone antagonist (%) | 28 | 38 | 24 | 17 | 0.283 |
Calcium channel antagonist (%) | 5 | 3 | 3 | 17 | 0.144 |
Digoxin (%) | 13 | 9 | 15 | 17 | 0.738 |
Ivabradine (%) | 3 | 0 | 3 | 8 | 0.292 |
Creatinine (umol/L) | 93 ± 24 | 96 ± 30 | 89 ± 19 | 95 ± 22 | 0.334 |
LVEF (%) | 26.6 ± 7.0 | 27.2 ± 7.1 | 28.2 ± 6.4 | 23.5 ± 6.5 | 0.095 |
LVEDVi (mL/m2) | 139 ± 35 | 137.2 ± 33.3 | 135.0 ± 40.5 | 152.0 ± 29.5 | 0.406 |
LVESVi (mL/m2) | 104 ± 34 | 101.5 ± 33.8 | 97.5 ± 36.1 | 117.6 ± 29.2 | 0.133 |